Special Issue "Vasodilators: New Insights"

A special issue of Pathophysiology (ISSN 1873-149X).

Deadline for manuscript submissions: 31 December 2022 | Viewed by 1913

Special Issue Editor

Dr. Olga Pecháňová
E-Mail Website
Guest Editor
Institute of Normal and Pathological Physiology, Centre of Experimental Medicine, Slovak Academy of Sciences, Bratislava, Slovakia
Interests: nitric oxide; polyphenolic compounds; cardiovascular system; hypertension; metabolic syndrome
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Vasodilators have been known for 120 years and yet our knowledge of them is still insufficient for successfully treating cardiovascular diseases, hypertension, angina pectoris, metabolic syndrome and other diseases requiring improved vasodilation. We, therefore, invite you to publish your latest results on the molecular nature, mechanisms, modifiability, effects and therapeutic possibilities of endogenous vasodilators, as well as the drugs that belong to them. Our Special Issue is mainly devoted to original knowledge in the field of c-AMP-, c-GMP- and hyperpolarization-mediated vasodilation, and PDE5 inhibitors and potassium channel openers, to central vasomotor control mechanisms, cold-induced vasodilation and other mechanisms of vasodilation. The Special Issue further focuses on modifiers of vasodilatory mechanisms, such as polyphenolic substances and many antioxidants; the targeted delivery of vasodilators, e.g., through nanoparticles; potential new vasodilators; and new perspectives on treatment options. Within this Special Issue, original articles, experimental results, clinical studies and more-extensive reviews will be published. We look forward to your contributions and cooperation.

Dr. Olga Pecháňová
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pathophysiology is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cardiovascular diseases
  • arteries
  • vasodilation
  • blood pressure
  • prostacyclin
  • nitric oxide
  • adenosine
  • hyperpolarization
  • polyphenolic substances
  • nanoparticles

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Article
Circulating Levels of Endothelin-1 and Big Endothelin-1 in Patients with Essential Hypertension
Pathophysiology 2021, 28(4), 489-495; https://doi.org/10.3390/pathophysiology28040031 - 25 Oct 2021
Viewed by 1265
Abstract
The role of endothelin-1 (ET-1) in the pathogenesis of hypertension (HTN) is not clearly established. There is evidence that its circulating levels are elevated in some forms of experimental and human HTN, but this was not a consistent finding. Based on these controversial [...] Read more.
The role of endothelin-1 (ET-1) in the pathogenesis of hypertension (HTN) is not clearly established. There is evidence that its circulating levels are elevated in some forms of experimental and human HTN, but this was not a consistent finding. Based on these controversial data, we tested serum levels of ET-1 and Big ET-1 (the precursor of ET-1) in patients with essential HTN, comparing the results with those of healthy normotensive controls. The levels of ET-1 and Big ET-1 were measured by ELISA. Our results in patients with essential HTN showed that the mean levels of ET-1 (5.01 ± 2.1 pg/mL) were significantly higher (F = 6.34, p = 0.0144) than the mean levels in the control group (3.2 ± 1.0 pg/mL). The levels of Big ET-1 in patients with essential HTN (0.377 ± 0.1 pmol/L) were similar to those in the control group (0.378 ± 0.07 pmol/L) and did not differ significantly (F = 0.00, p = 0.9531). These data suggest that ET-1, but not Big ET-1, may play an important role in the pathogenesis of primary HTN. Full article
(This article belongs to the Special Issue Vasodilators: New Insights)
Show Figures

Figure 1

Back to TopTop